A Clinical Utility Index for Selecting an Optimal Insulin Dosing Algorithm for LY2605541 in Patients with Type 2 Diabetes Pretreated with Basal Insulin
David H. Manner(Eli Lilly (United States)), Scott J. Jacober(Eli Lilly (United States)), Scott Berry(Queen's University), Yongming Qu(Eli Lilly (United States)), Brenda Gaydos(Eli Lilly (United States)), Junxiang Luo(Eli Lilly (United States))
Cited by 1
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
|Alzheimer s Research & Therapy|2021|818